Patients with an aggressive form of the disease, namely acute, lymphoma, and chronic with unfavorable prognostic factors (abnormal levels of blood urea nitrogen, lactate dehydrogenase, or albumin), have a poor prognosis with a median survival time (MST) of approximately 1 year [28], even when treated with combination chemotherapy. The gene discussed is ALB; the disease is lymphoma.